nodes	percent_of_prediction	percent_of_DWPC	metapath
Fesoterodine—CYP2D6—breast cancer	0.142	0.389	CbGaD
Fesoterodine—CYP3A4—breast cancer	0.122	0.334	CbGaD
Fesoterodine—ABCB1—breast cancer	0.101	0.278	CbGaD
Fesoterodine—ABCB1—Toremifene—breast cancer	0.0313	0.0776	CbGbCtD
Fesoterodine—CYP3A4—Exemestane—breast cancer	0.0271	0.0671	CbGbCtD
Fesoterodine—CYP2D6—Idarubicin—breast cancer	0.0244	0.0606	CbGbCtD
Fesoterodine—CYP3A4—Letrozole—breast cancer	0.023	0.057	CbGbCtD
Fesoterodine—ABCB1—Lapatinib—breast cancer	0.0228	0.0566	CbGbCtD
Fesoterodine—CYP3A4—Anastrozole—breast cancer	0.0205	0.0508	CbGbCtD
Fesoterodine—CYP3A4—Toremifene—breast cancer	0.0188	0.0465	CbGbCtD
Fesoterodine—CYP3A4—Fulvestrant—breast cancer	0.0174	0.0432	CbGbCtD
Fesoterodine—CYP3A4—Thiotepa—breast cancer	0.0155	0.0385	CbGbCtD
Fesoterodine—CYP3A4—Ixabepilone—breast cancer	0.0142	0.0352	CbGbCtD
Fesoterodine—CYP3A4—Lapatinib—breast cancer	0.0137	0.0339	CbGbCtD
Fesoterodine—ABCB1—Vinorelbine—breast cancer	0.0127	0.0314	CbGbCtD
Fesoterodine—CYP2D6—Vinorelbine—breast cancer	0.0119	0.0296	CbGbCtD
Fesoterodine—ABCB1—Tamoxifen—breast cancer	0.0114	0.0284	CbGbCtD
Fesoterodine—ABCB1—Mitoxantrone—breast cancer	0.0112	0.0277	CbGbCtD
Fesoterodine—CYP2D6—Tamoxifen—breast cancer	0.0108	0.0267	CbGbCtD
Fesoterodine—CYP3A4—Raloxifene—breast cancer	0.0104	0.0257	CbGbCtD
Fesoterodine—ABCB1—Gemcitabine—breast cancer	0.00985	0.0244	CbGbCtD
Fesoterodine—ABCB1—Paclitaxel—breast cancer	0.0089	0.0221	CbGbCtD
Fesoterodine—ABCB1—Irinotecan—breast cancer	0.00878	0.0218	CbGbCtD
Fesoterodine—ABCB1—Vinblastine—breast cancer	0.00781	0.0194	CbGbCtD
Fesoterodine—CYP3A4—Vinorelbine—breast cancer	0.00759	0.0188	CbGbCtD
Fesoterodine—CYP2D6—Vinblastine—breast cancer	0.00735	0.0182	CbGbCtD
Fesoterodine—CYP3A4—Tamoxifen—breast cancer	0.00685	0.017	CbGbCtD
Fesoterodine—CYP3A4—Mitoxantrone—breast cancer	0.00668	0.0166	CbGbCtD
Fesoterodine—ABCB1—Docetaxel—breast cancer	0.00643	0.016	CbGbCtD
Fesoterodine—CYP3A4—Paclitaxel—breast cancer	0.00533	0.0132	CbGbCtD
Fesoterodine—CYP3A4—Irinotecan—breast cancer	0.00526	0.013	CbGbCtD
Fesoterodine—ABCB1—Doxorubicin—breast cancer	0.0048	0.0119	CbGbCtD
Fesoterodine—CYP3A4—Vinblastine—breast cancer	0.00468	0.0116	CbGbCtD
Fesoterodine—ABCB1—Methotrexate—breast cancer	0.00465	0.0115	CbGbCtD
Fesoterodine—CYP2D6—Doxorubicin—breast cancer	0.00452	0.0112	CbGbCtD
Fesoterodine—CYP3A4—Docetaxel—breast cancer	0.00386	0.00956	CbGbCtD
Fesoterodine—CYP3A4—Doxorubicin—breast cancer	0.00287	0.00713	CbGbCtD
Fesoterodine—CHRM3—muscle of abdomen—breast cancer	0.000653	0.372	CbGeAlD
Fesoterodine—Tolterodine—CYP2D6—breast cancer	0.000199	0.368	CrCbGaD
Fesoterodine—Disopyramide—CYP3A4—breast cancer	0.00017	0.316	CrCbGaD
Fesoterodine—Tolterodine—CYP3A4—breast cancer	0.00017	0.316	CrCbGaD
Fesoterodine—CHRM5—epithelium—breast cancer	0.000139	0.0791	CbGeAlD
Fesoterodine—CHRM5—skin of body—breast cancer	0.000132	0.0753	CbGeAlD
Fesoterodine—Infestation—Methotrexate—breast cancer	9.39e-05	0.000572	CcSEcCtD
Fesoterodine—Alanine aminotransferase increased—Doxorubicin—breast cancer	9.3e-05	0.000566	CcSEcCtD
Fesoterodine—Vision blurred—Capecitabine—breast cancer	9.29e-05	0.000566	CcSEcCtD
Fesoterodine—Dysuria—Epirubicin—breast cancer	9.21e-05	0.000561	CcSEcCtD
Fesoterodine—Dizziness—Thiotepa—breast cancer	9.2e-05	0.00056	CcSEcCtD
Fesoterodine—Rash—Vinorelbine—breast cancer	9.19e-05	0.000559	CcSEcCtD
Fesoterodine—Dermatitis—Vinorelbine—breast cancer	9.18e-05	0.000559	CcSEcCtD
Fesoterodine—Upper respiratory tract infection—Epirubicin—breast cancer	9.16e-05	0.000558	CcSEcCtD
Fesoterodine—Urticaria—Fluorouracil—breast cancer	9.14e-05	0.000557	CcSEcCtD
Fesoterodine—Headache—Vinorelbine—breast cancer	9.13e-05	0.000556	CcSEcCtD
Fesoterodine—Palpitations—Docetaxel—breast cancer	8.99e-05	0.000548	CcSEcCtD
Fesoterodine—Cough—Docetaxel—breast cancer	8.88e-05	0.000541	CcSEcCtD
Fesoterodine—Angina pectoris—Doxorubicin—breast cancer	8.88e-05	0.000541	CcSEcCtD
Fesoterodine—Hepatobiliary disease—Methotrexate—breast cancer	8.88e-05	0.000541	CcSEcCtD
Fesoterodine—Insomnia—Paclitaxel—breast cancer	8.86e-05	0.00054	CcSEcCtD
Fesoterodine—Vertigo—Capecitabine—breast cancer	8.85e-05	0.000539	CcSEcCtD
Fesoterodine—Hypersensitivity—Irinotecan—breast cancer	8.85e-05	0.000539	CcSEcCtD
Fesoterodine—Hypersensitivity—Mitoxantrone—breast cancer	8.85e-05	0.000539	CcSEcCtD
Fesoterodine—Infestation—Epirubicin—breast cancer	8.78e-05	0.000535	CcSEcCtD
Fesoterodine—Infestation NOS—Epirubicin—breast cancer	8.78e-05	0.000535	CcSEcCtD
Fesoterodine—Rash—Thiotepa—breast cancer	8.77e-05	0.000534	CcSEcCtD
Fesoterodine—Dermatitis—Thiotepa—breast cancer	8.77e-05	0.000534	CcSEcCtD
Fesoterodine—Headache—Thiotepa—breast cancer	8.72e-05	0.000531	CcSEcCtD
Fesoterodine—Somnolence—Paclitaxel—breast cancer	8.71e-05	0.000531	CcSEcCtD
Fesoterodine—Palpitations—Capecitabine—breast cancer	8.71e-05	0.00053	CcSEcCtD
Fesoterodine—Chest pain—Docetaxel—breast cancer	8.67e-05	0.000528	CcSEcCtD
Fesoterodine—Nausea—Vinorelbine—breast cancer	8.65e-05	0.000527	CcSEcCtD
Fesoterodine—Dyspepsia—Paclitaxel—breast cancer	8.63e-05	0.000525	CcSEcCtD
Fesoterodine—Asthenia—Mitoxantrone—breast cancer	8.62e-05	0.000525	CcSEcCtD
Fesoterodine—Asthenia—Irinotecan—breast cancer	8.62e-05	0.000525	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	8.61e-05	0.000524	CcSEcCtD
Fesoterodine—Cough—Capecitabine—breast cancer	8.6e-05	0.000524	CcSEcCtD
Fesoterodine—Urinary tract infection—Epirubicin—breast cancer	8.54e-05	0.00052	CcSEcCtD
Fesoterodine—Dysuria—Doxorubicin—breast cancer	8.52e-05	0.000519	CcSEcCtD
Fesoterodine—Hypersensitivity—Fluorouracil—breast cancer	8.48e-05	0.000516	CcSEcCtD
Fesoterodine—Dry mouth—Docetaxel—breast cancer	8.47e-05	0.000516	CcSEcCtD
Fesoterodine—Upper respiratory tract infection—Doxorubicin—breast cancer	8.47e-05	0.000516	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Paclitaxel—breast cancer	8.46e-05	0.000515	CcSEcCtD
Fesoterodine—Fatigue—Paclitaxel—breast cancer	8.45e-05	0.000515	CcSEcCtD
Fesoterodine—Asthenia—Gemcitabine—breast cancer	8.4e-05	0.000511	CcSEcCtD
Fesoterodine—Chest pain—Capecitabine—breast cancer	8.39e-05	0.000511	CcSEcCtD
Fesoterodine—Constipation—Paclitaxel—breast cancer	8.38e-05	0.00051	CcSEcCtD
Fesoterodine—Confusional state—Docetaxel—breast cancer	8.38e-05	0.00051	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	8.33e-05	0.000507	CcSEcCtD
Fesoterodine—Urinary tract disorder—Methotrexate—breast cancer	8.32e-05	0.000507	CcSEcCtD
Fesoterodine—Hepatobiliary disease—Epirubicin—breast cancer	8.31e-05	0.000506	CcSEcCtD
Fesoterodine—Pruritus—Gemcitabine—breast cancer	8.28e-05	0.000504	CcSEcCtD
Fesoterodine—Nausea—Thiotepa—breast cancer	8.27e-05	0.000503	CcSEcCtD
Fesoterodine—Urethral disorder—Methotrexate—breast cancer	8.26e-05	0.000503	CcSEcCtD
Fesoterodine—Infection—Docetaxel—breast cancer	8.25e-05	0.000503	CcSEcCtD
Fesoterodine—Diarrhoea—Irinotecan—breast cancer	8.22e-05	0.000501	CcSEcCtD
Fesoterodine—Diarrhoea—Mitoxantrone—breast cancer	8.22e-05	0.000501	CcSEcCtD
Fesoterodine—Dry mouth—Capecitabine—breast cancer	8.2e-05	0.0005	CcSEcCtD
Fesoterodine—Nervous system disorder—Docetaxel—breast cancer	8.15e-05	0.000496	CcSEcCtD
Fesoterodine—Pruritus—Fluorouracil—breast cancer	8.14e-05	0.000496	CcSEcCtD
Fesoterodine—Infestation NOS—Doxorubicin—breast cancer	8.13e-05	0.000495	CcSEcCtD
Fesoterodine—Infestation—Doxorubicin—breast cancer	8.13e-05	0.000495	CcSEcCtD
Fesoterodine—Confusional state—Capecitabine—breast cancer	8.11e-05	0.000494	CcSEcCtD
Fesoterodine—Tachycardia—Docetaxel—breast cancer	8.11e-05	0.000494	CcSEcCtD
Fesoterodine—Feeling abnormal—Paclitaxel—breast cancer	8.08e-05	0.000492	CcSEcCtD
Fesoterodine—Skin disorder—Docetaxel—breast cancer	8.07e-05	0.000491	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Paclitaxel—breast cancer	8.01e-05	0.000488	CcSEcCtD
Fesoterodine—Diarrhoea—Gemcitabine—breast cancer	8.01e-05	0.000488	CcSEcCtD
Fesoterodine—Infection—Capecitabine—breast cancer	7.99e-05	0.000487	CcSEcCtD
Fesoterodine—Dizziness—Irinotecan—breast cancer	7.95e-05	0.000484	CcSEcCtD
Fesoterodine—Urinary tract infection—Doxorubicin—breast cancer	7.9e-05	0.000481	CcSEcCtD
Fesoterodine—Nervous system disorder—Capecitabine—breast cancer	7.89e-05	0.00048	CcSEcCtD
Fesoterodine—Eye disorder—Methotrexate—breast cancer	7.88e-05	0.00048	CcSEcCtD
Fesoterodine—Diarrhoea—Fluorouracil—breast cancer	7.87e-05	0.00048	CcSEcCtD
Fesoterodine—Tachycardia—Capecitabine—breast cancer	7.85e-05	0.000478	CcSEcCtD
Fesoterodine—Cardiac disorder—Methotrexate—breast cancer	7.82e-05	0.000476	CcSEcCtD
Fesoterodine—Skin disorder—Capecitabine—breast cancer	7.81e-05	0.000476	CcSEcCtD
Fesoterodine—Urinary tract disorder—Epirubicin—breast cancer	7.79e-05	0.000474	CcSEcCtD
Fesoterodine—Urticaria—Paclitaxel—breast cancer	7.79e-05	0.000474	CcSEcCtD
Fesoterodine—Oedema peripheral—Epirubicin—breast cancer	7.77e-05	0.000473	CcSEcCtD
Fesoterodine—Abdominal pain—Paclitaxel—breast cancer	7.75e-05	0.000472	CcSEcCtD
Fesoterodine—Urethral disorder—Epirubicin—breast cancer	7.73e-05	0.000471	CcSEcCtD
Fesoterodine—Hepatobiliary disease—Doxorubicin—breast cancer	7.69e-05	0.000468	CcSEcCtD
Fesoterodine—Dizziness—Fluorouracil—breast cancer	7.61e-05	0.000463	CcSEcCtD
Fesoterodine—Mediastinal disorder—Methotrexate—breast cancer	7.59e-05	0.000462	CcSEcCtD
Fesoterodine—Rash—Irinotecan—breast cancer	7.58e-05	0.000461	CcSEcCtD
Fesoterodine—Rash—Mitoxantrone—breast cancer	7.58e-05	0.000461	CcSEcCtD
Fesoterodine—Dermatitis—Mitoxantrone—breast cancer	7.57e-05	0.000461	CcSEcCtD
Fesoterodine—Dermatitis—Irinotecan—breast cancer	7.57e-05	0.000461	CcSEcCtD
Fesoterodine—Headache—Irinotecan—breast cancer	7.53e-05	0.000458	CcSEcCtD
Fesoterodine—Headache—Mitoxantrone—breast cancer	7.53e-05	0.000458	CcSEcCtD
Fesoterodine—Insomnia—Docetaxel—breast cancer	7.51e-05	0.000458	CcSEcCtD
Fesoterodine—Somnolence—Docetaxel—breast cancer	7.38e-05	0.00045	CcSEcCtD
Fesoterodine—Mental disorder—Methotrexate—breast cancer	7.38e-05	0.00045	CcSEcCtD
Fesoterodine—Rash—Gemcitabine—breast cancer	7.38e-05	0.000449	CcSEcCtD
Fesoterodine—Dermatitis—Gemcitabine—breast cancer	7.37e-05	0.000449	CcSEcCtD
Fesoterodine—Eye disorder—Epirubicin—breast cancer	7.37e-05	0.000449	CcSEcCtD
Fesoterodine—Headache—Gemcitabine—breast cancer	7.33e-05	0.000447	CcSEcCtD
Fesoterodine—Cardiac disorder—Epirubicin—breast cancer	7.32e-05	0.000446	CcSEcCtD
Fesoterodine—Dyspepsia—Docetaxel—breast cancer	7.31e-05	0.000445	CcSEcCtD
Fesoterodine—Insomnia—Capecitabine—breast cancer	7.27e-05	0.000443	CcSEcCtD
Fesoterodine—Rash—Fluorouracil—breast cancer	7.26e-05	0.000442	CcSEcCtD
Fesoterodine—Dermatitis—Fluorouracil—breast cancer	7.25e-05	0.000441	CcSEcCtD
Fesoterodine—Hypersensitivity—Paclitaxel—breast cancer	7.22e-05	0.00044	CcSEcCtD
Fesoterodine—Headache—Fluorouracil—breast cancer	7.21e-05	0.000439	CcSEcCtD
Fesoterodine—Urinary tract disorder—Doxorubicin—breast cancer	7.21e-05	0.000439	CcSEcCtD
Fesoterodine—Oedema peripheral—Doxorubicin—breast cancer	7.19e-05	0.000438	CcSEcCtD
Fesoterodine—Dysgeusia—Methotrexate—breast cancer	7.18e-05	0.000437	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Docetaxel—breast cancer	7.17e-05	0.000437	CcSEcCtD
Fesoterodine—Fatigue—Docetaxel—breast cancer	7.16e-05	0.000436	CcSEcCtD
Fesoterodine—Urethral disorder—Doxorubicin—breast cancer	7.15e-05	0.000436	CcSEcCtD
Fesoterodine—Nausea—Mitoxantrone—breast cancer	7.14e-05	0.000435	CcSEcCtD
Fesoterodine—Nausea—Irinotecan—breast cancer	7.14e-05	0.000435	CcSEcCtD
Fesoterodine—Mediastinal disorder—Epirubicin—breast cancer	7.11e-05	0.000433	CcSEcCtD
Fesoterodine—Constipation—Docetaxel—breast cancer	7.1e-05	0.000433	CcSEcCtD
Fesoterodine—Back pain—Methotrexate—breast cancer	7.1e-05	0.000432	CcSEcCtD
Fesoterodine—Dyspepsia—Capecitabine—breast cancer	7.08e-05	0.000431	CcSEcCtD
Fesoterodine—Asthenia—Paclitaxel—breast cancer	7.03e-05	0.000428	CcSEcCtD
Fesoterodine—Nausea—Gemcitabine—breast cancer	6.95e-05	0.000423	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Capecitabine—breast cancer	6.94e-05	0.000423	CcSEcCtD
Fesoterodine—Fatigue—Capecitabine—breast cancer	6.93e-05	0.000422	CcSEcCtD
Fesoterodine—Pruritus—Paclitaxel—breast cancer	6.93e-05	0.000422	CcSEcCtD
Fesoterodine—Vision blurred—Methotrexate—breast cancer	6.91e-05	0.000421	CcSEcCtD
Fesoterodine—Mental disorder—Epirubicin—breast cancer	6.91e-05	0.000421	CcSEcCtD
Fesoterodine—Constipation—Capecitabine—breast cancer	6.88e-05	0.000419	CcSEcCtD
Fesoterodine—Feeling abnormal—Docetaxel—breast cancer	6.85e-05	0.000417	CcSEcCtD
Fesoterodine—Nausea—Fluorouracil—breast cancer	6.84e-05	0.000416	CcSEcCtD
Fesoterodine—Eye disorder—Doxorubicin—breast cancer	6.82e-05	0.000415	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Docetaxel—breast cancer	6.79e-05	0.000414	CcSEcCtD
Fesoterodine—Cardiac disorder—Doxorubicin—breast cancer	6.77e-05	0.000412	CcSEcCtD
Fesoterodine—Flatulence—Epirubicin—breast cancer	6.76e-05	0.000412	CcSEcCtD
Fesoterodine—Dysgeusia—Epirubicin—breast cancer	6.72e-05	0.000409	CcSEcCtD
Fesoterodine—Diarrhoea—Paclitaxel—breast cancer	6.71e-05	0.000408	CcSEcCtD
Fesoterodine—Back pain—Epirubicin—breast cancer	6.64e-05	0.000404	CcSEcCtD
Fesoterodine—Feeling abnormal—Capecitabine—breast cancer	6.63e-05	0.000404	CcSEcCtD
Fesoterodine—Vertigo—Methotrexate—breast cancer	6.59e-05	0.000401	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Capecitabine—breast cancer	6.58e-05	0.0004	CcSEcCtD
Fesoterodine—Mediastinal disorder—Doxorubicin—breast cancer	6.58e-05	0.0004	CcSEcCtD
Fesoterodine—Abdominal pain—Docetaxel—breast cancer	6.57e-05	0.0004	CcSEcCtD
Fesoterodine—Dizziness—Paclitaxel—breast cancer	6.48e-05	0.000395	CcSEcCtD
Fesoterodine—Vision blurred—Epirubicin—breast cancer	6.47e-05	0.000394	CcSEcCtD
Fesoterodine—CHRM1—female reproductive system—breast cancer	6.46e-05	0.0367	CbGeAlD
Fesoterodine—Cough—Methotrexate—breast cancer	6.4e-05	0.00039	CcSEcCtD
Fesoterodine—Mental disorder—Doxorubicin—breast cancer	6.39e-05	0.000389	CcSEcCtD
Fesoterodine—Urticaria—Capecitabine—breast cancer	6.39e-05	0.000389	CcSEcCtD
Fesoterodine—Abdominal pain—Capecitabine—breast cancer	6.36e-05	0.000387	CcSEcCtD
Fesoterodine—CHRM3—adipose tissue—breast cancer	6.29e-05	0.0358	CbGeAlD
Fesoterodine—Flatulence—Doxorubicin—breast cancer	6.26e-05	0.000381	CcSEcCtD
Fesoterodine—Chest pain—Methotrexate—breast cancer	6.25e-05	0.00038	CcSEcCtD
Fesoterodine—Dysgeusia—Doxorubicin—breast cancer	6.22e-05	0.000379	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	6.2e-05	0.000378	CcSEcCtD
Fesoterodine—Rash—Paclitaxel—breast cancer	6.18e-05	0.000376	CcSEcCtD
Fesoterodine—Dermatitis—Paclitaxel—breast cancer	6.17e-05	0.000376	CcSEcCtD
Fesoterodine—Vertigo—Epirubicin—breast cancer	6.17e-05	0.000376	CcSEcCtD
Fesoterodine—Back pain—Doxorubicin—breast cancer	6.14e-05	0.000374	CcSEcCtD
Fesoterodine—Headache—Paclitaxel—breast cancer	6.14e-05	0.000374	CcSEcCtD
Fesoterodine—Hypersensitivity—Docetaxel—breast cancer	6.12e-05	0.000373	CcSEcCtD
Fesoterodine—Palpitations—Epirubicin—breast cancer	6.07e-05	0.000369	CcSEcCtD
Fesoterodine—Confusional state—Methotrexate—breast cancer	6.04e-05	0.000368	CcSEcCtD
Fesoterodine—CHRM2—endocrine gland—breast cancer	6e-05	0.0342	CbGeAlD
Fesoterodine—Cough—Epirubicin—breast cancer	5.99e-05	0.000365	CcSEcCtD
Fesoterodine—Vision blurred—Doxorubicin—breast cancer	5.99e-05	0.000365	CcSEcCtD
Fesoterodine—Asthenia—Docetaxel—breast cancer	5.96e-05	0.000363	CcSEcCtD
Fesoterodine—Infection—Methotrexate—breast cancer	5.95e-05	0.000362	CcSEcCtD
Fesoterodine—Hypersensitivity—Capecitabine—breast cancer	5.93e-05	0.000361	CcSEcCtD
Fesoterodine—Pruritus—Docetaxel—breast cancer	5.88e-05	0.000358	CcSEcCtD
Fesoterodine—Nervous system disorder—Methotrexate—breast cancer	5.87e-05	0.000358	CcSEcCtD
Fesoterodine—Chest pain—Epirubicin—breast cancer	5.84e-05	0.000356	CcSEcCtD
Fesoterodine—Nausea—Paclitaxel—breast cancer	5.82e-05	0.000354	CcSEcCtD
Fesoterodine—Skin disorder—Methotrexate—breast cancer	5.82e-05	0.000354	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	5.8e-05	0.000353	CcSEcCtD
Fesoterodine—CHRM3—female reproductive system—breast cancer	5.78e-05	0.0329	CbGeAlD
Fesoterodine—Asthenia—Capecitabine—breast cancer	5.77e-05	0.000351	CcSEcCtD
Fesoterodine—Dry mouth—Epirubicin—breast cancer	5.72e-05	0.000348	CcSEcCtD
Fesoterodine—Vertigo—Doxorubicin—breast cancer	5.71e-05	0.000348	CcSEcCtD
Fesoterodine—Pruritus—Capecitabine—breast cancer	5.69e-05	0.000346	CcSEcCtD
Fesoterodine—Diarrhoea—Docetaxel—breast cancer	5.68e-05	0.000346	CcSEcCtD
Fesoterodine—Confusional state—Epirubicin—breast cancer	5.65e-05	0.000344	CcSEcCtD
Fesoterodine—Palpitations—Doxorubicin—breast cancer	5.61e-05	0.000342	CcSEcCtD
Fesoterodine—Infection—Epirubicin—breast cancer	5.57e-05	0.000339	CcSEcCtD
Fesoterodine—Cough—Doxorubicin—breast cancer	5.54e-05	0.000338	CcSEcCtD
Fesoterodine—Diarrhoea—Capecitabine—breast cancer	5.5e-05	0.000335	CcSEcCtD
Fesoterodine—Nervous system disorder—Epirubicin—breast cancer	5.49e-05	0.000335	CcSEcCtD
Fesoterodine—Dizziness—Docetaxel—breast cancer	5.49e-05	0.000334	CcSEcCtD
Fesoterodine—Tachycardia—Epirubicin—breast cancer	5.47e-05	0.000333	CcSEcCtD
Fesoterodine—CHRM1—endocrine gland—breast cancer	5.46e-05	0.0311	CbGeAlD
Fesoterodine—Skin disorder—Epirubicin—breast cancer	5.44e-05	0.000331	CcSEcCtD
Fesoterodine—Insomnia—Methotrexate—breast cancer	5.41e-05	0.00033	CcSEcCtD
Fesoterodine—Chest pain—Doxorubicin—breast cancer	5.41e-05	0.000329	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	5.37e-05	0.000327	CcSEcCtD
Fesoterodine—Somnolence—Methotrexate—breast cancer	5.32e-05	0.000324	CcSEcCtD
Fesoterodine—Dizziness—Capecitabine—breast cancer	5.32e-05	0.000324	CcSEcCtD
Fesoterodine—Dry mouth—Doxorubicin—breast cancer	5.29e-05	0.000322	CcSEcCtD
Fesoterodine—Dyspepsia—Methotrexate—breast cancer	5.27e-05	0.000321	CcSEcCtD
Fesoterodine—CHRM3—female gonad—breast cancer	5.26e-05	0.0299	CbGeAlD
Fesoterodine—Rash—Docetaxel—breast cancer	5.24e-05	0.000319	CcSEcCtD
Fesoterodine—Dermatitis—Docetaxel—breast cancer	5.23e-05	0.000319	CcSEcCtD
Fesoterodine—Confusional state—Doxorubicin—breast cancer	5.23e-05	0.000318	CcSEcCtD
Fesoterodine—Headache—Docetaxel—breast cancer	5.2e-05	0.000317	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Methotrexate—breast cancer	5.17e-05	0.000315	CcSEcCtD
Fesoterodine—Fatigue—Methotrexate—breast cancer	5.16e-05	0.000314	CcSEcCtD
Fesoterodine—Infection—Doxorubicin—breast cancer	5.15e-05	0.000314	CcSEcCtD
Fesoterodine—Nervous system disorder—Doxorubicin—breast cancer	5.08e-05	0.00031	CcSEcCtD
Fesoterodine—Rash—Capecitabine—breast cancer	5.07e-05	0.000309	CcSEcCtD
Fesoterodine—Insomnia—Epirubicin—breast cancer	5.07e-05	0.000309	CcSEcCtD
Fesoterodine—Dermatitis—Capecitabine—breast cancer	5.07e-05	0.000309	CcSEcCtD
Fesoterodine—Tachycardia—Doxorubicin—breast cancer	5.06e-05	0.000308	CcSEcCtD
Fesoterodine—Headache—Capecitabine—breast cancer	5.04e-05	0.000307	CcSEcCtD
Fesoterodine—Skin disorder—Doxorubicin—breast cancer	5.04e-05	0.000307	CcSEcCtD
Fesoterodine—Somnolence—Epirubicin—breast cancer	4.98e-05	0.000303	CcSEcCtD
Fesoterodine—Nausea—Docetaxel—breast cancer	4.93e-05	0.0003	CcSEcCtD
Fesoterodine—Feeling abnormal—Methotrexate—breast cancer	4.93e-05	0.0003	CcSEcCtD
Fesoterodine—Dyspepsia—Epirubicin—breast cancer	4.93e-05	0.0003	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Methotrexate—breast cancer	4.9e-05	0.000298	CcSEcCtD
Fesoterodine—CHRM3—endocrine gland—breast cancer	4.89e-05	0.0278	CbGeAlD
Fesoterodine—Gastrointestinal disorder—Epirubicin—breast cancer	4.84e-05	0.000295	CcSEcCtD
Fesoterodine—Fatigue—Epirubicin—breast cancer	4.83e-05	0.000294	CcSEcCtD
Fesoterodine—Constipation—Epirubicin—breast cancer	4.79e-05	0.000292	CcSEcCtD
Fesoterodine—Nausea—Capecitabine—breast cancer	4.78e-05	0.000291	CcSEcCtD
Fesoterodine—Urticaria—Methotrexate—breast cancer	4.76e-05	0.00029	CcSEcCtD
Fesoterodine—Abdominal pain—Methotrexate—breast cancer	4.73e-05	0.000288	CcSEcCtD
Fesoterodine—Insomnia—Doxorubicin—breast cancer	4.69e-05	0.000286	CcSEcCtD
Fesoterodine—Feeling abnormal—Epirubicin—breast cancer	4.62e-05	0.000281	CcSEcCtD
Fesoterodine—Somnolence—Doxorubicin—breast cancer	4.61e-05	0.000281	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Epirubicin—breast cancer	4.58e-05	0.000279	CcSEcCtD
Fesoterodine—Dyspepsia—Doxorubicin—breast cancer	4.56e-05	0.000278	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Doxorubicin—breast cancer	4.48e-05	0.000273	CcSEcCtD
Fesoterodine—Fatigue—Doxorubicin—breast cancer	4.47e-05	0.000272	CcSEcCtD
Fesoterodine—Urticaria—Epirubicin—breast cancer	4.45e-05	0.000271	CcSEcCtD
Fesoterodine—Constipation—Doxorubicin—breast cancer	4.43e-05	0.00027	CcSEcCtD
Fesoterodine—Abdominal pain—Epirubicin—breast cancer	4.43e-05	0.00027	CcSEcCtD
Fesoterodine—Hypersensitivity—Methotrexate—breast cancer	4.41e-05	0.000269	CcSEcCtD
Fesoterodine—Asthenia—Methotrexate—breast cancer	4.3e-05	0.000262	CcSEcCtD
Fesoterodine—Feeling abnormal—Doxorubicin—breast cancer	4.27e-05	0.00026	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Doxorubicin—breast cancer	4.24e-05	0.000258	CcSEcCtD
Fesoterodine—Pruritus—Methotrexate—breast cancer	4.24e-05	0.000258	CcSEcCtD
Fesoterodine—Hypersensitivity—Epirubicin—breast cancer	4.13e-05	0.000251	CcSEcCtD
Fesoterodine—Urticaria—Doxorubicin—breast cancer	4.12e-05	0.000251	CcSEcCtD
Fesoterodine—Abdominal pain—Doxorubicin—breast cancer	4.1e-05	0.00025	CcSEcCtD
Fesoterodine—Diarrhoea—Methotrexate—breast cancer	4.1e-05	0.000249	CcSEcCtD
Fesoterodine—Asthenia—Epirubicin—breast cancer	4.02e-05	0.000245	CcSEcCtD
Fesoterodine—Pruritus—Epirubicin—breast cancer	3.96e-05	0.000241	CcSEcCtD
Fesoterodine—Dizziness—Methotrexate—breast cancer	3.96e-05	0.000241	CcSEcCtD
Fesoterodine—Diarrhoea—Epirubicin—breast cancer	3.83e-05	0.000233	CcSEcCtD
Fesoterodine—Hypersensitivity—Doxorubicin—breast cancer	3.82e-05	0.000233	CcSEcCtD
Fesoterodine—Rash—Methotrexate—breast cancer	3.77e-05	0.00023	CcSEcCtD
Fesoterodine—Dermatitis—Methotrexate—breast cancer	3.77e-05	0.00023	CcSEcCtD
Fesoterodine—Headache—Methotrexate—breast cancer	3.75e-05	0.000228	CcSEcCtD
Fesoterodine—Asthenia—Doxorubicin—breast cancer	3.72e-05	0.000226	CcSEcCtD
Fesoterodine—ABCB1—embryo—breast cancer	3.71e-05	0.0211	CbGeAlD
Fesoterodine—Dizziness—Epirubicin—breast cancer	3.7e-05	0.000226	CcSEcCtD
Fesoterodine—Pruritus—Doxorubicin—breast cancer	3.67e-05	0.000223	CcSEcCtD
Fesoterodine—Nausea—Methotrexate—breast cancer	3.56e-05	0.000217	CcSEcCtD
Fesoterodine—Diarrhoea—Doxorubicin—breast cancer	3.55e-05	0.000216	CcSEcCtD
Fesoterodine—Rash—Epirubicin—breast cancer	3.53e-05	0.000215	CcSEcCtD
Fesoterodine—Dermatitis—Epirubicin—breast cancer	3.53e-05	0.000215	CcSEcCtD
Fesoterodine—Headache—Epirubicin—breast cancer	3.51e-05	0.000214	CcSEcCtD
Fesoterodine—Dizziness—Doxorubicin—breast cancer	3.43e-05	0.000209	CcSEcCtD
Fesoterodine—Nausea—Epirubicin—breast cancer	3.33e-05	0.000203	CcSEcCtD
Fesoterodine—Rash—Doxorubicin—breast cancer	3.27e-05	0.000199	CcSEcCtD
Fesoterodine—Dermatitis—Doxorubicin—breast cancer	3.27e-05	0.000199	CcSEcCtD
Fesoterodine—Headache—Doxorubicin—breast cancer	3.25e-05	0.000198	CcSEcCtD
Fesoterodine—CYP3A4—female reproductive system—breast cancer	3.18e-05	0.0181	CbGeAlD
Fesoterodine—CYP2D6—female reproductive system—breast cancer	3.12e-05	0.0178	CbGeAlD
Fesoterodine—Nausea—Doxorubicin—breast cancer	3.08e-05	0.000188	CcSEcCtD
Fesoterodine—ABCB1—epithelium—breast cancer	3.03e-05	0.0172	CbGeAlD
Fesoterodine—CYP2D6—female gonad—breast cancer	2.84e-05	0.0162	CbGeAlD
Fesoterodine—ABCB1—endometrium—breast cancer	2.71e-05	0.0154	CbGeAlD
Fesoterodine—CYP3A4—endocrine gland—breast cancer	2.69e-05	0.0153	CbGeAlD
Fesoterodine—CYP2D6—endocrine gland—breast cancer	2.64e-05	0.015	CbGeAlD
Fesoterodine—ABCB1—uterus—breast cancer	2.5e-05	0.0142	CbGeAlD
Fesoterodine—ABCB1—pituitary gland—breast cancer	2.46e-05	0.014	CbGeAlD
Fesoterodine—ABCB1—adipose tissue—breast cancer	2.45e-05	0.0139	CbGeAlD
Fesoterodine—ABCB1—female reproductive system—breast cancer	2.25e-05	0.0128	CbGeAlD
Fesoterodine—ABCB1—adrenal gland—breast cancer	2.19e-05	0.0125	CbGeAlD
Fesoterodine—ABCB1—bone marrow—breast cancer	2.12e-05	0.0121	CbGeAlD
Fesoterodine—ABCB1—female gonad—breast cancer	2.05e-05	0.0116	CbGeAlD
Fesoterodine—ABCB1—endocrine gland—breast cancer	1.9e-05	0.0108	CbGeAlD
Fesoterodine—ABCB1—lymph node—breast cancer	1.31e-05	0.00748	CbGeAlD
Fesoterodine—CHRM3—Signaling Pathways—EGF—breast cancer	3.84e-06	5.87e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CDKN1A—breast cancer	3.84e-06	5.86e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—PTEN—breast cancer	3.83e-06	5.85e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—EGF—breast cancer	3.81e-06	5.81e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—GPX1—breast cancer	3.81e-06	5.81e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CCND1—breast cancer	3.8e-06	5.8e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—JUN—breast cancer	3.79e-06	5.79e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—TYMS—breast cancer	3.79e-06	5.78e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—CYP1A1—breast cancer	3.77e-06	5.75e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CTNNB1—breast cancer	3.76e-06	5.75e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MAPK8—breast cancer	3.75e-06	5.72e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—NCOR1—breast cancer	3.75e-06	5.72e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—GSTM1—breast cancer	3.75e-06	5.72e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PLA2G4A—breast cancer	3.75e-06	5.72e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—AKT1—breast cancer	3.74e-06	5.71e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—ERCC2—breast cancer	3.74e-06	5.71e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—MAPK3—breast cancer	3.74e-06	5.7e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—MAPK3—breast cancer	3.72e-06	5.69e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MMP9—breast cancer	3.69e-06	5.63e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—MAPK3—breast cancer	3.69e-06	5.63e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CDKN1A—breast cancer	3.68e-06	5.61e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—PTEN—breast cancer	3.67e-06	5.6e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—BRAF—breast cancer	3.67e-06	5.6e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—BRAF—breast cancer	3.66e-06	5.58e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CYP17A1—breast cancer	3.64e-06	5.56e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—BRAF—breast cancer	3.62e-06	5.53e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ENO1—breast cancer	3.6e-06	5.5e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PTGS1—breast cancer	3.6e-06	5.5e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MAPK8—breast cancer	3.59e-06	5.48e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—GPX1—breast cancer	3.59e-06	5.48e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—AKT1—breast cancer	3.58e-06	5.46e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IGF1—breast cancer	3.57e-06	5.45e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—AKT2—breast cancer	3.57e-06	5.45e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PIK3CB—breast cancer	3.56e-06	5.44e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IGF1—breast cancer	3.56e-06	5.44e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—AKT2—breast cancer	3.56e-06	5.43e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—EGFR—breast cancer	3.55e-06	5.43e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—SRC—breast cancer	3.55e-06	5.42e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—CYP1A1—breast cancer	3.55e-06	5.42e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—EGFR—breast cancer	3.54e-06	5.41e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CYP2D6—breast cancer	3.53e-06	5.39e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PTGS2—breast cancer	3.53e-06	5.39e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IGF1—breast cancer	3.53e-06	5.38e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—AKT2—breast cancer	3.52e-06	5.38e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—ERCC2—breast cancer	3.52e-06	5.38e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—MTHFR—breast cancer	3.51e-06	5.36e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—EGFR—breast cancer	3.51e-06	5.36e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—NCOA2—breast cancer	3.47e-06	5.29e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—VEGFA—breast cancer	3.46e-06	5.28e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PIK3CD—breast cancer	3.43e-06	5.24e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—STAT3—breast cancer	3.43e-06	5.23e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3CD—breast cancer	3.42e-06	5.22e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—SRC—breast cancer	3.4e-06	5.19e-05	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—PIK3CA—breast cancer	3.4e-06	5.19e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—SERPINE1—breast cancer	3.39e-06	5.18e-05	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—PIK3CA—breast cancer	3.39e-06	5.17e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3CD—breast cancer	3.39e-06	5.17e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—SERPINE1—breast cancer	3.38e-06	5.16e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—FASN—breast cancer	3.36e-06	5.13e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—KRAS—breast cancer	3.36e-06	5.13e-05	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—PIK3CA—breast cancer	3.35e-06	5.12e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—BCHE—breast cancer	3.35e-06	5.11e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—SERPINE1—breast cancer	3.35e-06	5.11e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—KRAS—breast cancer	3.35e-06	5.11e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—KRAS—breast cancer	3.31e-06	5.06e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—VEGFA—breast cancer	3.31e-06	5.06e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—MTHFR—breast cancer	3.31e-06	5.05e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—SLC5A5—breast cancer	3.31e-06	5.05e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—STAT3—breast cancer	3.28e-06	5.01e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MAPK3—breast cancer	3.27e-06	5e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—CAV1—breast cancer	3.24e-06	4.95e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—NOS3—breast cancer	3.24e-06	4.94e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—NOS3—breast cancer	3.23e-06	4.93e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—NOS3—breast cancer	3.2e-06	4.88e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—SLC2A1—breast cancer	3.19e-06	4.88e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—NQO1—breast cancer	3.19e-06	4.88e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MYC—breast cancer	3.18e-06	4.86e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—TGFB1—breast cancer	3.18e-06	4.85e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MAPK3—breast cancer	3.13e-06	4.79e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—EGFR—breast cancer	3.11e-06	4.75e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—PIK3CA—breast cancer	3.08e-06	4.71e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PTEN—breast cancer	3.08e-06	4.7e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—PIK3CA—breast cancer	3.08e-06	4.7e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MDM2—breast cancer	3.07e-06	4.69e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CYP1B1—breast cancer	3.06e-06	4.68e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MDM2—breast cancer	3.06e-06	4.68e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—RAF1—breast cancer	3.06e-06	4.67e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—CAV1—breast cancer	3.05e-06	4.66e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—RAF1—breast cancer	3.05e-06	4.66e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MYC—breast cancer	3.05e-06	4.66e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—RELA—breast cancer	3.05e-06	4.65e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—PIK3CA—breast cancer	3.05e-06	4.65e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—TGFB1—breast cancer	3.04e-06	4.64e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—RELA—breast cancer	3.04e-06	4.64e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MDM2—breast cancer	3.03e-06	4.63e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—ERBB2—breast cancer	3.03e-06	4.63e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—RAF1—breast cancer	3.02e-06	4.61e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—ERBB2—breast cancer	3.02e-06	4.61e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—RELA—breast cancer	3.01e-06	4.59e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—HSP90AA1—breast cancer	3e-06	4.59e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—ERBB2—breast cancer	2.99e-06	4.57e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PIK3CB—breast cancer	2.99e-06	4.56e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MTOR—breast cancer	2.99e-06	4.56e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—EGFR—breast cancer	2.98e-06	4.55e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3CB—breast cancer	2.98e-06	4.55e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MTOR—breast cancer	2.98e-06	4.55e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CG—breast cancer	2.95e-06	4.51e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3CB—breast cancer	2.95e-06	4.51e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MTOR—breast cancer	2.95e-06	4.51e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—KRAS—breast cancer	2.94e-06	4.49e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—NCOA1—breast cancer	2.92e-06	4.46e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CYP19A1—breast cancer	2.88e-06	4.4e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—STK11—breast cancer	2.88e-06	4.4e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CXCL8—breast cancer	2.87e-06	4.39e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CXCL8—breast cancer	2.86e-06	4.37e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—HRAS—breast cancer	2.85e-06	4.36e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—HRAS—breast cancer	2.85e-06	4.34e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CXCL8—breast cancer	2.84e-06	4.33e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—HRAS—breast cancer	2.82e-06	4.3e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—KRAS—breast cancer	2.82e-06	4.3e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CDKN1B—breast cancer	2.81e-06	4.28e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CDKN1B—breast cancer	2.8e-06	4.27e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CG—breast cancer	2.78e-06	4.25e-05	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—AKT1—breast cancer	2.78e-06	4.24e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CDKN1B—breast cancer	2.77e-06	4.23e-05	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—AKT1—breast cancer	2.77e-06	4.22e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CASP3—breast cancer	2.75e-06	4.2e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IL2—breast cancer	2.75e-06	4.19e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CASP3—breast cancer	2.74e-06	4.18e-05	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—AKT1—breast cancer	2.74e-06	4.18e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IL2—breast cancer	2.74e-06	4.18e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—IL6—breast cancer	2.73e-06	4.17e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—IL6—breast cancer	2.72e-06	4.16e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CASP3—breast cancer	2.71e-06	4.14e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IL2—breast cancer	2.71e-06	4.14e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—PIK3CA—breast cancer	2.7e-06	4.13e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—IL6—breast cancer	2.7e-06	4.12e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—COMT—breast cancer	2.68e-06	4.09e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CCND1—breast cancer	2.68e-06	4.09e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—JUN—breast cancer	2.67e-06	4.08e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CCND1—breast cancer	2.67e-06	4.07e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GSTP1—breast cancer	2.66e-06	4.07e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—JUN—breast cancer	2.66e-06	4.06e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CTNNB1—breast cancer	2.65e-06	4.05e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CTNNB1—breast cancer	2.64e-06	4.03e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CCND1—breast cancer	2.64e-06	4.03e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—JUN—breast cancer	2.64e-06	4.03e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—HMOX1—breast cancer	2.63e-06	4.01e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ITPR1—breast cancer	2.62e-06	4e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CTNNB1—breast cancer	2.62e-06	3.99e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—TP53—breast cancer	2.61e-06	3.99e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MMP9—breast cancer	2.6e-06	3.97e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CD—breast cancer	2.59e-06	3.96e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MMP9—breast cancer	2.59e-06	3.95e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CDKN1A—breast cancer	2.59e-06	3.95e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—PIK3CA—breast cancer	2.59e-06	3.95e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PTEN—breast cancer	2.58e-06	3.94e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CDKN1A—breast cancer	2.58e-06	3.94e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PTEN—breast cancer	2.57e-06	3.93e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MMP9—breast cancer	2.56e-06	3.92e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—ALB—breast cancer	2.56e-06	3.91e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CDKN1A—breast cancer	2.56e-06	3.9e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PTEN—breast cancer	2.55e-06	3.89e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MAPK8—breast cancer	2.53e-06	3.86e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ABCB1—breast cancer	2.52e-06	3.85e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—AKT1—breast cancer	2.52e-06	3.85e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MAPK8—breast cancer	2.52e-06	3.85e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—AKT1—breast cancer	2.51e-06	3.84e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—TP53—breast cancer	2.5e-06	3.82e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—HRAS—breast cancer	2.5e-06	3.82e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MAPK8—breast cancer	2.49e-06	3.81e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—AKT1—breast cancer	2.49e-06	3.8e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—TYMS—breast cancer	2.48e-06	3.78e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—NOS3—breast cancer	2.45e-06	3.74e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—NCOR1—breast cancer	2.45e-06	3.74e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PLA2G4A—breast cancer	2.45e-06	3.74e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GSTM1—breast cancer	2.45e-06	3.74e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CD—breast cancer	2.44e-06	3.73e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—ALB—breast cancer	2.41e-06	3.68e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—SRC—breast cancer	2.4e-06	3.66e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—HRAS—breast cancer	2.39e-06	3.66e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—IL6—breast cancer	2.39e-06	3.65e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—SRC—breast cancer	2.39e-06	3.65e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—SRC—breast cancer	2.36e-06	3.61e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GPX1—breast cancer	2.34e-06	3.58e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—VEGFA—breast cancer	2.33e-06	3.56e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—VEGFA—breast cancer	2.33e-06	3.55e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CYP1A1—breast cancer	2.32e-06	3.54e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—STAT3—breast cancer	2.31e-06	3.53e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—NOS3—breast cancer	2.31e-06	3.52e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—VEGFA—breast cancer	2.3e-06	3.52e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—STAT3—breast cancer	2.3e-06	3.52e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ERCC2—breast cancer	2.3e-06	3.51e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—IL6—breast cancer	2.29e-06	3.5e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—STAT3—breast cancer	2.28e-06	3.48e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CB—breast cancer	2.26e-06	3.45e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PTGS2—breast cancer	2.24e-06	3.42e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—AKT1—breast cancer	2.21e-06	3.37e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MAPK3—breast cancer	2.21e-06	3.37e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MAPK3—breast cancer	2.2e-06	3.36e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MAPK3—breast cancer	2.18e-06	3.33e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PIK3CA—breast cancer	2.17e-06	3.32e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—MTHFR—breast cancer	2.16e-06	3.3e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MYC—breast cancer	2.15e-06	3.28e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—TGFB1—breast cancer	2.14e-06	3.27e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MYC—breast cancer	2.14e-06	3.27e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—TGFB1—breast cancer	2.13e-06	3.26e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CB—breast cancer	2.13e-06	3.25e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MYC—breast cancer	2.12e-06	3.24e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—AKT1—breast cancer	2.11e-06	3.23e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—TGFB1—breast cancer	2.11e-06	3.23e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PTGS2—breast cancer	2.11e-06	3.22e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—EGFR—breast cancer	2.1e-06	3.21e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—EGFR—breast cancer	2.09e-06	3.2e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—EGFR—breast cancer	2.07e-06	3.16e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CAV1—breast cancer	2e-06	3.05e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—KRAS—breast cancer	1.98e-06	3.03e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—KRAS—breast cancer	1.98e-06	3.02e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—KRAS—breast cancer	1.96e-06	2.99e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PTEN—breast cancer	1.95e-06	2.98e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PTEN—breast cancer	1.84e-06	2.81e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PIK3CA—breast cancer	1.82e-06	2.78e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CG—breast cancer	1.82e-06	2.78e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3CA—breast cancer	1.82e-06	2.77e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3CA—breast cancer	1.8e-06	2.75e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—AKT1—breast cancer	1.77e-06	2.71e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—TP53—breast cancer	1.76e-06	2.69e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—TP53—breast cancer	1.76e-06	2.68e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—TP53—breast cancer	1.74e-06	2.66e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—HRAS—breast cancer	1.69e-06	2.57e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—HRAS—breast cancer	1.68e-06	2.57e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—HRAS—breast cancer	1.66e-06	2.54e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IL6—breast cancer	1.61e-06	2.46e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IL6—breast cancer	1.61e-06	2.46e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CD—breast cancer	1.6e-06	2.44e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IL6—breast cancer	1.59e-06	2.43e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ALB—breast cancer	1.58e-06	2.41e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—NOS3—breast cancer	1.51e-06	2.3e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—AKT1—breast cancer	1.49e-06	2.27e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—AKT1—breast cancer	1.48e-06	2.27e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—AKT1—breast cancer	1.47e-06	2.24e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CB—breast cancer	1.39e-06	2.13e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PTGS2—breast cancer	1.38e-06	2.11e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CA—breast cancer	1.38e-06	2.1e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CA—breast cancer	1.3e-06	1.98e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PTEN—breast cancer	1.2e-06	1.84e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—AKT1—breast cancer	1.13e-06	1.72e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—AKT1—breast cancer	1.06e-06	1.62e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CA—breast cancer	8.49e-07	1.3e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—AKT1—breast cancer	6.94e-07	1.06e-05	CbGpPWpGaD
